1 00:00:06,080 --> 00:00:10,513 On this episode of Translating Proteomics, host Andreas Humer of 2 00:00:10,529 --> 00:00:14,809 Nautilus Biotechnology discusses advances in Alzheimer's 3 00:00:14,857 --> 00:00:19,774 research with Special guest and CurieBio drug maker in residence, 4 00:00:19,890 --> 00:00:25,329 Dr. Sarah DeVos. Their conversation focuses on the impact 5 00:00:25,417 --> 00:00:30,595 molecular diagnostics have had on Alzheimer's research, recent Alzheimer's 6 00:00:30,635 --> 00:00:35,987 drug approvals, and the future of Alzheimer's research. Now here 7 00:00:36,011 --> 00:00:38,615 is Andreas to introduce Sarah. 8 00:00:39,635 --> 00:00:43,947 Welcome back to Translating Proteomics. In today's episode, I 9 00:00:43,971 --> 00:00:46,563 have the great honor of speaking with Special guest Sarah 10 00:00:46,579 --> 00:00:51,211 DeVos. Sarah has over 15 years experience in translational research 11 00:00:51,403 --> 00:00:56,517 focused on neurodegenerative diseases. She was a post drug fellow 12 00:00:56,621 --> 00:01:00,397 at Washington University in St. Louis as well as the Massachusetts 13 00:01:00,461 --> 00:01:05,261 General Hospital before she joined Denali Therapeutics. And recently 14 00:01:05,333 --> 00:01:10,061 she left Denali Therapeutics to join Curie Bio as a drug maker 15 00:01:10,093 --> 00:01:14,117 in residence. Sarah shares that one of her driving forces in 16 00:01:14,141 --> 00:01:18,333 her career is a desire to do work that has meaningful, positive 17 00:01:18,389 --> 00:01:23,151 impact on patient lives. With that in mind, I'm very excited to 18 00:01:23,183 --> 00:01:27,103 have Sarah on the podcast to discuss Alzheimer's biomarkers in 19 00:01:27,119 --> 00:01:31,703 the context of clinical practice. In this conversation, I 20 00:01:31,719 --> 00:01:34,535 hope we'll cover how biomarkers are used in Alzheimer's 21 00:01:34,575 --> 00:01:38,759 diagnosis, treatment, and clinical trials. What additional 22 00:01:38,807 --> 00:01:43,831 information we need from new Alzheimer's biomarkers, and what 23 00:01:43,863 --> 00:01:48,441 role does proteomics play in making new ultramarkers and advancing 24 00:01:48,513 --> 00:01:52,657 patient care. With that, I welcome you, Sara, to the podcast. 25 00:01:52,801 --> 00:01:54,329 Thank you very much for having me. 26 00:01:54,457 --> 00:01:58,497 So let me start out asking you, how did you get into the field 27 00:01:58,521 --> 00:02:01,473 of neurodegenerative diseases? What attracted you to this field 28 00:02:01,489 --> 00:02:02,369 of science? 29 00:02:02,537 --> 00:02:08,329 Yeah, so for me, it basically stems from family. So I'm growing 30 00:02:08,377 --> 00:02:11,955 up. Everyone in my family gets Alzheimer's disease. And so for me, 31 00:02:11,995 --> 00:02:15,667 it was very like, why does that happen? I grew up in a small 32 00:02:15,771 --> 00:02:19,163 farm town in Michigan. It was almost a way of life for my family. 33 00:02:19,219 --> 00:02:23,043 Everyone just accepts it. And so for me, growing up, I wanted to 34 00:02:23,099 --> 00:02:26,691 see, can I change that, essentially. So it was fascinating 35 00:02:26,763 --> 00:02:29,827 from, like, a science perspective. And so I think when 36 00:02:29,851 --> 00:02:33,483 I was in middle school, I decided I wanted to go into research 37 00:02:33,579 --> 00:02:37,107 for Alzheimer's disease. No one in my family had, like, gone 38 00:02:37,131 --> 00:02:41,417 into science at all. So it was entirely, like, untreaded. And when 39 00:02:41,441 --> 00:02:44,593 I did undergrad, serendipitously found a lab that 40 00:02:44,609 --> 00:02:47,633 did tau research for Alzheimer's. And then I just kind 41 00:02:47,649 --> 00:02:50,921 of snowballed and just kept going with it because it was really, 42 00:02:50,993 --> 00:02:54,553 I think, looking at tau and its correlation to cognitive decline 43 00:02:54,609 --> 00:02:58,265 in Alzheimer's disease, it's such a direct Correlation that, looking 44 00:02:58,305 --> 00:03:01,945 at that, then I basically just made my career out of studying that 45 00:03:01,985 --> 00:03:05,643 part of Alzheimer's disease. So the tau pathology piece, and then 46 00:03:05,659 --> 00:03:08,771 I did my grad school work in it, my postdoc denali, I worked on 47 00:03:08,803 --> 00:03:15,395 TAO because it to me felt very druggable, very directly related 48 00:03:15,435 --> 00:03:19,575 to the disease. And Alzheimer's impacts so many families 49 00:03:19,915 --> 00:03:23,563 throughout the US throughout the world. But for me, I wanted to 50 00:03:23,579 --> 00:03:25,971 study it in the context of my own personal family. 51 00:03:26,083 --> 00:03:29,963 So for you, this is clearly very personal. I think, as you already 52 00:03:30,019 --> 00:03:35,487 mentioned, the number of people that suffer through neurodegeneration 53 00:03:35,631 --> 00:03:38,647 is going to increase dramatically over the next few decades. 54 00:03:38,791 --> 00:03:43,607 So given the tools we have today, do you think we have sufficient 55 00:03:43,671 --> 00:03:48,759 tools to sort of, first of all, diagnose Alzheimer's? And how 56 00:03:48,767 --> 00:03:50,315 do you see this moving forward? 57 00:03:50,695 --> 00:03:55,263 I think, yeah. So the advent of biomarkers and Alzheimer's disease 58 00:03:55,399 --> 00:03:59,593 changed everything, right? It changed research, basic research, 59 00:03:59,729 --> 00:04:03,849 it changed drug discovery, drug development, clinical trials. 60 00:04:03,977 --> 00:04:07,233 And so a lot of times I draw the parallel with oncology, right? 61 00:04:07,289 --> 00:04:11,009 So when you think of oncology, you think of being able to image 62 00:04:11,057 --> 00:04:14,577 the tumor, to be able to look at it in real time and track it in 63 00:04:14,601 --> 00:04:17,793 real time. And that enables the advent of a bunch of therapeutics 64 00:04:17,849 --> 00:04:23,489 for oncology. For Alzheimer's disease. I like my blood brain barrier. 65 00:04:23,577 --> 00:04:27,497 I like that it keeps the things out, but it also makes it 66 00:04:27,521 --> 00:04:31,569 very difficult to then be able to assess in real time what's happening 67 00:04:31,617 --> 00:04:35,305 in your brain. So being able to, for example, with PET pib, right, 68 00:04:35,345 --> 00:04:40,785 so Pittsburgh compound B binds to amyloid beta plaques. That alone 69 00:04:40,945 --> 00:04:44,313 changed the entire game of how we think about Alzheimer's disease, 70 00:04:44,369 --> 00:04:48,737 clinical trials, being able to properly enroll patients. So for 71 00:04:48,761 --> 00:04:52,025 a long time, we're running Alzheimer's trials because dementia 72 00:04:52,065 --> 00:04:55,433 is a large umbrella. Alzheimer's is the largest part of 73 00:04:55,449 --> 00:04:59,289 that umbrella, but it's not the whole thing. So if you're going 74 00:04:59,297 --> 00:05:03,609 to run a trial, you want to make sure that you have participants 75 00:05:03,697 --> 00:05:06,729 that actually have the pathology of interest. Otherwise 76 00:05:06,817 --> 00:05:09,825 it's going to be a moot point. Your data is going to be super messy. 77 00:05:09,865 --> 00:05:12,433 It's going to be very variable because you're not even recruiting 78 00:05:12,529 --> 00:05:14,641 people who have Alzheimer's, you're recruiting people who have 79 00:05:14,673 --> 00:05:20,023 other types of dementia. And so that single biomarker alone changed 80 00:05:20,039 --> 00:05:23,351 the whole game for Alzheimer's disease. And now we're be getting 81 00:05:23,503 --> 00:05:26,967 a bit more sophisticated. We're studying tau. We have a really 82 00:05:26,991 --> 00:05:30,727 good tau PET ligand to be able to monitor tau pathology in the brain. 83 00:05:30,791 --> 00:05:34,719 Because for Alzheimer's you have to have both amyloid and tau 84 00:05:34,767 --> 00:05:38,727 pathology in order for it to be properly Alzheimer's. But for 85 00:05:38,751 --> 00:05:41,607 a long time, and even when I started in the field, the only way 86 00:05:41,631 --> 00:05:44,945 to actually diagnose someone with Alzheimer's disease was at autopsy. 87 00:05:45,065 --> 00:05:47,737 And at that point you're obviously too late. 88 00:05:47,801 --> 00:05:48,745 Arguably too late. 89 00:05:48,785 --> 00:05:48,961 Yes. 90 00:05:48,993 --> 00:05:53,401 Sorry. I recently was at the Association Alzheimer's Association's 91 00:05:53,593 --> 00:05:58,049 international meeting and you couldn't but notice that there, you 92 00:05:58,057 --> 00:06:01,073 know, it was all about biomarkers. I mean, a lot of companies 93 00:06:01,129 --> 00:06:04,977 have jumped into the space, but double clicking on, you know, 94 00:06:05,001 --> 00:06:08,129 the availability of biomarkers a little bit, there's still some 95 00:06:08,177 --> 00:06:13,781 very major challenges. I can imagine. I mean, one of the key diagnosis 96 00:06:13,933 --> 00:06:19,213 or key diagnostic tools that you mentioned is the PET scan, but 97 00:06:19,229 --> 00:06:22,261 it's expensive and it's certainly not very accessible in 98 00:06:22,293 --> 00:06:26,501 some cases. So how have biomarkers, the blood based biomarkers, 99 00:06:26,533 --> 00:06:29,613 helped us and maybe what are the limitations for those? 100 00:06:29,789 --> 00:06:35,613 Yeah, I 100% agree. Right. PET imaging is great from like a larger 101 00:06:35,669 --> 00:06:40,255 macro scale, it's good to get started. It allows us to look into 102 00:06:40,295 --> 00:06:43,807 the brain. You can see the basically spatial resolution of where 103 00:06:43,831 --> 00:06:49,183 the pathology is. But it's incredibly expensive. It is not accessible 104 00:06:49,239 --> 00:06:53,103 throughout the world. And so to be able to do a plasma pull and 105 00:06:53,119 --> 00:06:55,759 be able to analyze that, it just becomes way more tractable. 106 00:06:55,807 --> 00:07:00,647 Right. So now we have scale, now we have access. And so we're 107 00:07:00,711 --> 00:07:04,231 moving in a good direction in terms of both amyloid beta and tau. 108 00:07:04,303 --> 00:07:08,157 Right. So for amyloid beta, perhaps a bit counterintuitive, but 109 00:07:08,181 --> 00:07:11,917 you actually see a reduction of a beta in the blood. It's because 110 00:07:11,941 --> 00:07:15,821 your brain is a sink. So it just holds it for tau, I'm sure you 111 00:07:15,853 --> 00:07:20,629 saw, right, phospho tau217, huge increase in interest because 112 00:07:20,717 --> 00:07:24,305 there is a more direct relationship between tau pathology, 113 00:07:24,605 --> 00:07:28,453 neuronal death, cognitive decline. That's a really nice axis, 114 00:07:28,589 --> 00:07:31,621 amyloid beta. You can have people who have a brain full of amyloid 115 00:07:31,653 --> 00:07:35,053 beta and they're cognitively normal, so you need both of them. 116 00:07:35,149 --> 00:07:38,309 And tau is the one that's a bit closer to the actual neuron dying. 117 00:07:38,437 --> 00:07:41,885 And so for a long time the field has really been searching hard 118 00:07:41,965 --> 00:07:45,085 to find a blood based biomarker because you can do CSF 119 00:07:45,125 --> 00:07:49,901 poles as well. But that's also very cumbersome. People don't like 120 00:07:49,933 --> 00:07:55,245 to do it. And so it's uncomfortable, not painful per se, 121 00:07:55,285 --> 00:07:58,797 but it's a scary thing, right, to have a needle go into the lumbar 122 00:07:58,861 --> 00:08:02,881 space and pull csf. So by Making that switch to blood based 123 00:08:02,913 --> 00:08:07,097 biomarkers, you can get so much more data, right? And you can 124 00:08:07,121 --> 00:08:10,441 get really nice longitudinal data at like a bunch of different 125 00:08:10,473 --> 00:08:13,577 time points. Because with pet, because it's radioactivity, you're 126 00:08:13,601 --> 00:08:16,497 also limited in terms of the number you can do a year. And so 127 00:08:16,521 --> 00:08:19,513 it allows us to really carefully understand the dynamics 128 00:08:19,569 --> 00:08:23,913 of disease progression for the first set. Right. We do need to be 129 00:08:23,929 --> 00:08:28,431 able to go back to correlate what it is in blood versus pathology 130 00:08:28,503 --> 00:08:33,647 in the brain. So you really do need to build a solid data set for 131 00:08:33,671 --> 00:08:37,455 us to feel comfortable relying on a blood based biomarker and not 132 00:08:37,495 --> 00:08:41,175 having to do the PET imaging. But the field is really, really rapidly 133 00:08:41,215 --> 00:08:46,311 moving in that direction. And I think it was 20, 20, 2021 when 134 00:08:46,343 --> 00:08:50,719 we really saw this big uptick in tau blood based biomarkers. And 135 00:08:50,807 --> 00:08:54,663 now it's all the rage. So it's super fun, right, to be in that space, 136 00:08:54,759 --> 00:09:00,851 to watch it move in an arguably exponent. And when you have 137 00:09:00,883 --> 00:09:04,315 something that starts to work, you see people come in, you see people 138 00:09:04,355 --> 00:09:08,123 get excited. I got a text from my mother last Sunday and she's like, 139 00:09:08,139 --> 00:09:11,531 I'm hearing these things about phosphatau and blood. Is that real? 140 00:09:11,643 --> 00:09:15,507 She's not a scientist, she's an incredible woman. But the fact 141 00:09:15,531 --> 00:09:19,139 that it's hitting people like my mom in a rural part of Michigan 142 00:09:19,307 --> 00:09:23,691 shows people are getting excited. And if you have that, then 143 00:09:23,763 --> 00:09:27,895 more companies can rely on it. Drug discovery increases, drug development 144 00:09:28,015 --> 00:09:32,615 increases, and you just enter into this really exciting phase for 145 00:09:32,695 --> 00:09:36,167 things like Alzheimer's. People can start to feel that it's 146 00:09:36,231 --> 00:09:39,991 starting to happen. We're not there. We do not have a cure. But 147 00:09:40,143 --> 00:09:43,367 building off of biomarkers, you have a lot more companies entering 148 00:09:43,391 --> 00:09:46,047 into the space. And that's what you want, right? You want more 149 00:09:46,111 --> 00:09:49,751 companies to come in, test more ideas so that we have multiple 150 00:09:49,783 --> 00:09:50,599 shots on goal. 151 00:09:50,687 --> 00:09:55,409 Yeah. So just to sort of rephrase what you just said, I think 152 00:09:55,497 --> 00:09:59,605 there's the first hurdle we had to be taken in the field where 153 00:10:00,025 --> 00:10:04,785 you have to essentially find an easy, accessible biomarker that 154 00:10:04,825 --> 00:10:09,313 reflects the pathology in the brain. And I guess with the tau in 155 00:10:09,329 --> 00:10:14,249 combination with amyloid beta, we have a very highly accessible 156 00:10:14,377 --> 00:10:19,201 combination of biomarkers that is very good in predicting Alzheimer's 157 00:10:19,273 --> 00:10:22,841 or neurodegeneration relatively early on. The other part 158 00:10:22,873 --> 00:10:25,801 that I sort of sensed during the meeting was that people now, 159 00:10:25,833 --> 00:10:30,945 with that biomarker available, feel incredibly empowered to do something 160 00:10:31,065 --> 00:10:36,457 for the people. There were recently a few drugs approved in 161 00:10:36,481 --> 00:10:40,097 that space. And so let's talk a little bit about the drugs that 162 00:10:40,121 --> 00:10:44,673 have been approved and maybe how the biomarkers sort of help in 163 00:10:44,689 --> 00:10:48,275 the treatment or even the clinical trials, if that, if that's, 164 00:10:48,615 --> 00:10:50,127 you know, correlating as well. 165 00:10:50,231 --> 00:10:54,455 Yeah, right. So there's a series of anti amyloid beta drugs. 166 00:10:54,495 --> 00:10:56,991 So these are all monoclonal antibodies. They come in different 167 00:10:57,023 --> 00:10:59,727 flavors, they bind to different parts of amyloid. So you've 168 00:10:59,751 --> 00:11:06,247 got Aducanumab or Aduhelm, Lecanemab or Leqimbi and then Donanemab, 169 00:11:06,351 --> 00:11:08,687 which I always forget the commercial name. It was very recently 170 00:11:08,751 --> 00:11:13,227 announced. So different flavors that bind at like different 171 00:11:13,311 --> 00:11:15,427 properties, different parts of amyloid beta. But they all are doing 172 00:11:15,451 --> 00:11:17,827 the same thing. They're all trying to remove the amyloid beta 173 00:11:17,851 --> 00:11:21,419 plaque from the brain. And you can see that very clearly with PET 174 00:11:21,467 --> 00:11:24,187 pib. Right. So that's kind of like the major one for clinical trials 175 00:11:24,211 --> 00:11:27,715 that they're monitoring is can you see a reduction in amyloid beta? 176 00:11:27,835 --> 00:11:30,043 That's the target engagement. That's what you want to do. And then 177 00:11:30,059 --> 00:11:32,323 the question was, if you can do that, then what happens? In terms 178 00:11:32,339 --> 00:11:36,867 of clinical and cognitive decline, it is by no means a cure. 179 00:11:36,971 --> 00:11:42,389 However, seeing three different trials begins to build 180 00:11:42,437 --> 00:11:46,253 confidence in the biology. So we just need to understand what is 181 00:11:46,269 --> 00:11:49,621 the impact of lowering amyloid beta. What does that mean in the 182 00:11:49,653 --> 00:11:52,661 long term? What does that mean for things like tau, for example? 183 00:11:52,813 --> 00:11:56,829 And there's I think some really, you know, with tau pet really 184 00:11:56,917 --> 00:12:00,213 powerful data when you do essentially also a post hoc analysis. 185 00:12:00,349 --> 00:12:04,477 If you have tau pathology in your brain, an anti amyloid beta 186 00:12:04,501 --> 00:12:08,093 is not going to do as much. So it really begins to help us understand 187 00:12:08,149 --> 00:12:11,061 the basic biology of where you are in the disease. Because Alzheimer's 188 00:12:11,093 --> 00:12:15,557 is super tricky. It starts 20 years prior to any cognitive decline. 189 00:12:15,621 --> 00:12:19,613 Right. That has made it really difficult to be able to appropriately 190 00:12:19,669 --> 00:12:24,309 intervene now, because we're able to slow the disease by 20, 30%. 191 00:12:24,397 --> 00:12:27,853 Because we know that, yes, when you do lower plaques, we know 192 00:12:27,869 --> 00:12:33,517 this based on biomarkers. We see 27 to 30ish percent slowering. 193 00:12:33,701 --> 00:12:38,171 Then we can say, what does that mean by way of other biomarkers 194 00:12:38,243 --> 00:12:42,419 such as tau? What does that mean for the interplay, the timing? 195 00:12:42,587 --> 00:12:46,459 So now we know we need to go earlier and earlier and earlier in 196 00:12:46,467 --> 00:12:51,619 the course of disease, such that the earliest you can go, if 197 00:12:51,627 --> 00:12:54,363 you have someone who is mild cognitive impairment, the earliest 198 00:12:54,419 --> 00:12:57,403 moment for cognitive decline, they will always do better with an 199 00:12:57,419 --> 00:13:01,203 amyloid beta therapy versus someone who is mild or moderate, 200 00:13:01,379 --> 00:13:04,227 essentially by moderate if you have tau pathology and anti amyloid 201 00:13:04,251 --> 00:13:07,327 beta therapies, not going to work for you. But we know it only 202 00:13:07,391 --> 00:13:12,367 because of amyloid beta, PET imaging, tau PET imaging and now 203 00:13:12,391 --> 00:13:15,967 we're moving to blood based biomarkers. So the PET imaging allows 204 00:13:15,991 --> 00:13:20,039 us to like very crudely understand where we sit, but a blood 205 00:13:20,087 --> 00:13:23,711 based biomarker allows us to get way more granular. Right. So 206 00:13:23,743 --> 00:13:28,047 then you can say, all right, you come in, you've got early phospho 207 00:13:28,071 --> 00:13:32,547 tau217 signal. We're not seeing a ton in brain yet, but we 208 00:13:32,571 --> 00:13:36,827 see a little bit. So we think that an anti amyloid therapy alone 209 00:13:36,931 --> 00:13:40,059 is not going to be sufficient for you. Now we want to shift that 210 00:13:40,107 --> 00:13:42,795 person over to something more of like a tau based therapeutic. 211 00:13:42,835 --> 00:13:45,475 And there are ones out there, right? There were some tau antibodies 212 00:13:45,635 --> 00:13:49,427 for N terminus, did not work very well. But mid domain those are 213 00:13:49,451 --> 00:13:52,019 looking potentially encouraging. There's tau asos which 214 00:13:52,027 --> 00:13:55,979 I had worked on before. So then it allows you to redirect a 215 00:13:56,027 --> 00:13:59,219 person. It's almost like a personalized medicine approach built 216 00:13:59,267 --> 00:14:03,019 off of blood based biomarkers that allow us to say this therapy 217 00:14:03,067 --> 00:14:07,267 or this therapy or this therapy, but again entirely enabled 218 00:14:07,331 --> 00:14:10,771 by biomarkers, which is just, it shows you the power of what you 219 00:14:10,803 --> 00:14:11,987 can do with that. 220 00:14:12,131 --> 00:14:15,507 It's exciting to see. And I think the other portion that's really 221 00:14:15,691 --> 00:14:18,975 interesting here, that most of this happened within a very short 222 00:14:19,435 --> 00:14:22,011 period of time. In fact, if you look at the literature, it's 223 00:14:22,043 --> 00:14:25,339 literally the last three, four years the entire field exploded. 224 00:14:25,387 --> 00:14:26,009 Right. 225 00:14:26,187 --> 00:14:30,981 But I wonder whether as we talk about the disease being a disease 226 00:14:31,013 --> 00:14:36,141 that start 20 years before you actually notice it in terms of cognitive 227 00:14:36,213 --> 00:14:40,741 decline. We have good biomarkers. Can you imagine having 228 00:14:40,893 --> 00:14:47,293 additional biomarkers that help us navigate those 20 years when. 229 00:14:47,309 --> 00:14:50,653 You do something like pet pep because it is invasive, because it 230 00:14:50,669 --> 00:14:54,675 is expensive, people are not lining up. Medicare is not going 231 00:14:54,675 --> 00:14:59,643 to cover you to get a pet PEB at the age of in your late 30s. They're 232 00:14:59,659 --> 00:15:03,619 not going to do that. So in order for us to move in that direction 233 00:15:03,667 --> 00:15:06,067 to go earlier and earlier. Earlier you want something that's 234 00:15:06,091 --> 00:15:10,379 a bit cheaper, more accessible so that we can start to build that 235 00:15:10,427 --> 00:15:15,475 data set such that it is covered by insurance programs. It 236 00:15:15,515 --> 00:15:19,945 is something that people get more and more excited about. I think 237 00:15:19,985 --> 00:15:22,217 drug development in general is quite tricky because you have to 238 00:15:22,241 --> 00:15:25,761 start with the disease and then you have to demonstrate some 239 00:15:25,833 --> 00:15:30,897 efficacy to get traction to then go earlier. For example, if 240 00:15:30,921 --> 00:15:34,513 there was, let's say neuroinflammation is A big part of 241 00:15:34,529 --> 00:15:38,761 Alzheimer's disease. It is one of the spaces that we lack biomarkers 242 00:15:38,793 --> 00:15:42,577 in to this day. So we have great biomarkers for the pathology. 243 00:15:42,721 --> 00:15:46,987 So if I look at a brain, I see plaques, I see tau tangles, got great 244 00:15:47,011 --> 00:15:50,331 biomarkers for that. When it comes to neuroinflammation, that's 245 00:15:50,363 --> 00:15:54,395 a big gap, but is a big part of the disease. So could there be 246 00:15:54,435 --> 00:15:59,379 a blood based biomarker where you see an uptick in gfap, an uptick 247 00:15:59,427 --> 00:16:04,035 in a microglial gene way earlier, and then you can hinge on 248 00:16:04,075 --> 00:16:07,635 that and be like, okay, so we think that this person might convert 249 00:16:07,795 --> 00:16:11,843 to mild cognitive impairment in the next five years. Therefore, 250 00:16:11,899 --> 00:16:14,539 we would want to start an anti amyloid beta therapy at this point. 251 00:16:14,587 --> 00:16:18,117 Because if you can get it super early, an anti amyloid might 252 00:16:18,141 --> 00:16:21,141 be sufficient. You might not even need to target tau at that point. 253 00:16:21,213 --> 00:16:22,909 It may arrest the disease early enough. 254 00:16:22,997 --> 00:16:27,301 Exactly, exactly. I mean, prevention is always better than 255 00:16:27,333 --> 00:16:31,293 reversal. Every indication. This is not neuroscience based. Like 256 00:16:31,389 --> 00:16:34,917 every disease, if you can prevent it, your odds and your chance 257 00:16:34,941 --> 00:16:36,597 of success go way, way up. 258 00:16:36,701 --> 00:16:41,781 So do you think that the need for these new biomarkers is currently 259 00:16:41,853 --> 00:16:46,385 limited, you know, because we don't have the right technologies, 260 00:16:47,045 --> 00:16:50,301 or is it limited because, you know, we're still working through 261 00:16:50,373 --> 00:16:54,981 the appropriate clinical trials? Where do you think is, are 262 00:16:55,013 --> 00:16:56,853 the opportunities in general there? 263 00:16:56,989 --> 00:17:02,869 Yeah, I think it's definitely multifactorial. I think the sensitivity 264 00:17:02,997 --> 00:17:05,453 of the assays is probably one of our biggest limitations. 265 00:17:05,589 --> 00:17:05,973 Okay. 266 00:17:06,029 --> 00:17:09,873 And so, you know, when you do a plasma draw, things like phospho 267 00:17:09,889 --> 00:17:12,593 tau217, we haven't been able to see for a long time because our 268 00:17:12,609 --> 00:17:16,057 assays weren't sensitive enough for it. We weren't. You wanna 269 00:17:16,081 --> 00:17:19,921 be able to do something that's very targeted in a space of untarget 270 00:17:20,033 --> 00:17:25,809 proteomics on target RNA seq, for example, you lose that sensitivity. 271 00:17:25,857 --> 00:17:29,873 Right. You have breadth, not depth. And so being able to find 272 00:17:29,929 --> 00:17:34,137 assays that allow us to profile both breadth and depth would 273 00:17:34,161 --> 00:17:37,493 be hugely valuable to just start to tease these things out. 274 00:17:37,649 --> 00:17:42,037 We also want to rely on genetics. Being able to go for familial 275 00:17:42,101 --> 00:17:45,197 Alzheimer's disease, for example, gives you power in terms 276 00:17:45,221 --> 00:17:50,013 of, unfortunately, these people will 100% convert. So then 277 00:17:50,029 --> 00:17:52,373 it allows us to track it. Earlier, when I was in grad school 278 00:17:52,389 --> 00:17:56,741 at Washu, I was privileged to be able to watch the Diane trials. 279 00:17:56,773 --> 00:18:00,677 So dominantly inherited Alzheimer's network. And there it's 280 00:18:00,701 --> 00:18:05,335 kind of twofold. One is understanding therapeutic timing. 281 00:18:05,415 --> 00:18:08,751 So if we treat this, what will that have in terms of an impact? 282 00:18:08,903 --> 00:18:11,831 But arguably, I'd say one of the more important in terms of the 283 00:18:11,863 --> 00:18:14,767 whole field is understanding the biomarker changes. And so they 284 00:18:14,791 --> 00:18:19,887 track these patients over time. So from early there's no pathology, 285 00:18:20,071 --> 00:18:23,791 they're totally fine. And then they just track them every year, 286 00:18:23,863 --> 00:18:28,247 two years over time. And that data set has been super powerful. 287 00:18:28,351 --> 00:18:31,035 And you can argue there are going to be some changes between 288 00:18:32,825 --> 00:18:36,057 familial Alzheimer's, if you have an APP mutation or a pre senolar 289 00:18:36,081 --> 00:18:41,321 mutation versus late onset Alzheimer's, but en masse, they're 290 00:18:41,353 --> 00:18:44,041 pretty similar. Right. You have the same pathology. The time 291 00:18:44,073 --> 00:18:47,849 course could slightly change, but being able to rely on those genetic 292 00:18:47,897 --> 00:18:52,497 populations to inform the later stage is hugely, hugely helpful. 293 00:18:52,601 --> 00:18:55,681 It gives us a starting point, right. And then we can say, all right, 294 00:18:55,753 --> 00:18:58,825 now we've got breadth, now we're going to go into depth on specific 295 00:18:58,865 --> 00:19:01,695 biomarkers that we found in genetic cohorts. Now we're going 296 00:19:01,695 --> 00:19:05,015 to apply that to a larger population. But when you go into 297 00:19:05,055 --> 00:19:08,359 like something like late onset, more sporadic cases, it's 298 00:19:08,407 --> 00:19:13,279 really difficult to motivate people to come in to do lumbar punctures, 299 00:19:13,367 --> 00:19:16,567 to get PET imaging. Right. Those are more invasive techniques. 300 00:19:16,751 --> 00:19:21,687 And there is a bit of a chicken and egg where if you don't 301 00:19:21,711 --> 00:19:24,871 have a therapy, people tend to, and I don't blame them, say why 302 00:19:24,903 --> 00:19:25,023 would. 303 00:19:25,039 --> 00:19:28,167 I do that particularly they're non symptomatic. It's like, why would 304 00:19:28,191 --> 00:19:32,395 I go to a doctor and get, get a procedure if I don't have any problems? 305 00:19:32,435 --> 00:19:36,291 Right. You mentioned those genetic populations that have been 306 00:19:36,323 --> 00:19:41,179 incredibly helpful because they basically create or limit a 307 00:19:41,187 --> 00:19:44,211 lot of the variables that we typically have for sporadic diseases. 308 00:19:44,283 --> 00:19:48,067 Right, let's talk about genetics for a little bit there. 309 00:19:48,171 --> 00:19:52,243 So recently there was a proposal, actually in one, I think 310 00:19:52,259 --> 00:19:55,419 it was in nature medicine saying we should treat Alzheimer's 311 00:19:55,467 --> 00:19:59,231 actually, particularly for patients that have an APOE epsilon 312 00:19:59,303 --> 00:20:03,759 4 mutation as a genetic disease. Because it's very clear 313 00:20:03,807 --> 00:20:08,367 that people with that mutation essentially proceed to neurodegenerative 314 00:20:08,471 --> 00:20:15,447 diseases much larger, much quicker. So with this in mind, what 315 00:20:15,471 --> 00:20:19,035 else do we see in the Alzheimer field evolving? 316 00:20:19,335 --> 00:20:26,713 Yeah, so APOE is today still the most reliable kind of genetic 317 00:20:26,769 --> 00:20:29,897 factor for sporadic Alzheimer's disease. Right. So we 318 00:20:29,921 --> 00:20:32,993 know very clearly the odds ratio. So if you have, you know, 319 00:20:33,049 --> 00:20:37,600 APOE 4, 4, so you have two alleles and the odds ratio is like 320 00:20:37,662 --> 00:20:40,963 14 or 15 fold increase chance, it's essentially 100%. Right. Like 321 00:20:41,025 --> 00:20:45,937 you could dabble and say like 95 to 100% or 92 to 100%. But it's 322 00:20:46,081 --> 00:20:50,893 very clear that, that you're moving in that direction. The field 323 00:20:50,949 --> 00:20:54,173 has been looking for other genetic markers. So there are a lot 324 00:20:54,189 --> 00:20:57,925 of microglial genes that can be up a little bit here and there. 325 00:20:58,045 --> 00:21:01,405 None of them come close to apoe like apoe, when you do a Manhattan 326 00:21:01,445 --> 00:21:05,765 plot, it blows them all out of the water. But it does help us understand 327 00:21:05,805 --> 00:21:09,493 a bit of the biology. And so it helps us understand what do we 328 00:21:09,509 --> 00:21:13,309 think about trem2, what do we think about pill array, some of these 329 00:21:13,357 --> 00:21:17,517 genetic aspects that have little increases or decreases here 330 00:21:17,541 --> 00:21:21,705 and there. It just helps us understand the biology a bit, which 331 00:21:21,745 --> 00:21:25,169 then helps us understand what biomarkers should we be looking for. 332 00:21:25,217 --> 00:21:29,377 Should we be looking for TREM2 levels, for example? Can we do that 333 00:21:29,401 --> 00:21:33,481 in CSF? Can we do it in plasma? Should we be understanding 334 00:21:33,553 --> 00:21:37,913 a pet imager? Because that was so powerful when it came to the pathologies? 335 00:21:38,089 --> 00:21:41,937 Is there a way to understand inflammation states in the brain 336 00:21:42,001 --> 00:21:45,457 with an imaging agent to then help guide us in terms of when's 337 00:21:45,481 --> 00:21:48,679 the best time to do a plasma draw or things like that? And so 338 00:21:48,727 --> 00:21:54,111 it allows it to, basically you have an anchor point, it points you 339 00:21:54,143 --> 00:21:57,839 in some direction. It's more of guide rails. It's not like absolutely 340 00:21:57,887 --> 00:22:02,007 this, but then we can build off of that, understand the biology, 341 00:22:02,071 --> 00:22:03,015 and then try and translate. 342 00:22:03,055 --> 00:22:07,975 That back to biomarker. So clearly, with the ability to measure 343 00:22:08,015 --> 00:22:11,927 those mutations, we probably have another really powerful tool 344 00:22:12,071 --> 00:22:17,455 that now we can tell people that they may have sporadic Alzheimer's 345 00:22:18,065 --> 00:22:23,457 tendencies. I became recently aware of a small company called Synapse 346 00:22:23,481 --> 00:22:27,097 DX that actually took a very different approach to diagnosing 347 00:22:27,201 --> 00:22:30,497 Alzheimer's. What they do is basically take a skin cell and then 348 00:22:30,521 --> 00:22:34,305 they grow it in a dish for a little bit. And it turns out because 349 00:22:34,465 --> 00:22:41,257 your brain and your skin come from the same development line, when 350 00:22:41,281 --> 00:22:47,009 you actually take those fiber plasts from your skin, if you have 351 00:22:47,097 --> 00:22:50,977 actually Alzheimer's or you are developing Alzheimer's, the cells 352 00:22:51,001 --> 00:22:55,265 have a very different shape. They ineffectually clump up. Whereas 353 00:22:55,345 --> 00:22:58,305 if you do not have Alzheimer's or the tendency of Alzheimer's, they 354 00:22:58,345 --> 00:23:01,969 actually form nice elongated cells. And so that's a very simple 355 00:23:02,017 --> 00:23:05,793 test that differentiates Alzheimer's clitoris from other neurodegenerative 356 00:23:05,849 --> 00:23:08,081 diseases. And so when I heard this, I was like, this is an interesting 357 00:23:08,113 --> 00:23:12,129 new approach. I wonder whether we need maybe other approaches in 358 00:23:12,137 --> 00:23:15,237 the biomarker space. And one of them I've been Thinking about 359 00:23:15,301 --> 00:23:21,421 is there's clearly literature emerging thinking about neuroprotective 360 00:23:21,533 --> 00:23:25,981 functions that the body has. And so maybe we should also think 361 00:23:26,013 --> 00:23:30,145 about biomarkers that says, oh, yeah, you definitely have a tendency 362 00:23:31,725 --> 00:23:36,185 to develop Alzheimer's, but you also have a protective function. 363 00:23:37,005 --> 00:23:40,525 Yeah, I mean, when you think of the odds ratio with a lot of these 364 00:23:40,565 --> 00:23:44,947 genes, we think about them, usually it was like, you've increased 365 00:23:44,971 --> 00:23:48,043 your risk. But there are certain genetic factors that can 366 00:23:48,059 --> 00:23:51,315 say, no, no, you are now protective APOE. There is the flip, 367 00:23:51,355 --> 00:23:56,091 right? So 4 increases your chance, 2 reduces your chance. Right. 368 00:23:56,203 --> 00:24:00,219 And so there are those opportunities within the genetic 369 00:24:00,267 --> 00:24:03,555 space to start to define those. I still think it basically 370 00:24:03,595 --> 00:24:06,843 just leads to the biology of understanding which way you want 371 00:24:06,859 --> 00:24:10,013 to move certain things. So should we agonize something, should 372 00:24:10,029 --> 00:24:13,861 we antagonize? And that's based off of some of those neuroprotective 373 00:24:13,893 --> 00:24:17,557 markers. So when I think of glial genes, for example, PLC gamma 374 00:24:17,621 --> 00:24:21,389 is one where you want to basically, if you have a mutation, 375 00:24:21,477 --> 00:24:24,109 it can be protective. It just leads you to the biology. It helps 376 00:24:24,117 --> 00:24:27,305 you understand. All right, which way do I want to move certain 377 00:24:27,605 --> 00:24:35,133 microglial states? I think understanding the timing of neuroinflammation, 378 00:24:35,229 --> 00:24:39,165 which way you want to move it, that is a huge gap in the field. 379 00:24:39,245 --> 00:24:41,785 There's a lot of data, data out there that we really want to 380 00:24:41,825 --> 00:24:48,129 understand. The timing part of it. The skin fibroblast is fascinating 381 00:24:48,217 --> 00:24:51,009 in terms of, like, what does that mean? What does that mean for 382 00:24:51,057 --> 00:24:54,233 timing? So if you were to pull, you know, so like, I have a 383 00:24:54,249 --> 00:24:57,217 punch biopsy scar actually, on my arm. I did a study when I was 384 00:24:57,241 --> 00:25:00,445 a postdoc. You know, you got to. You got to feed yourself somehow. 385 00:25:01,145 --> 00:25:04,521 And so it was one of those where, like, if you were able to 386 00:25:04,553 --> 00:25:10,819 do that longitudinally, right? So like, well before early stages, 387 00:25:10,987 --> 00:25:13,483 a bit later, and just understand what that looks like, 388 00:25:13,539 --> 00:25:16,563 then that becomes really powerful. It is a bit difficult, 389 00:25:16,619 --> 00:25:20,467 right, to collect within one snapshot because then you need huge 390 00:25:20,531 --> 00:25:23,395 numbers of patients, right? Alzheimer's disease is just incredibly 391 00:25:23,435 --> 00:25:27,539 multifactorial. It is not like, you know, you get it here and 392 00:25:27,547 --> 00:25:30,483 then two years later this, and then two years later this. It's just 393 00:25:30,579 --> 00:25:33,563 very, very different. Like, even within my own family, right, 394 00:25:33,619 --> 00:25:37,643 I've had grandparents who declined very quickly, and then I 395 00:25:37,659 --> 00:25:41,515 had grandparents that, you know, 13, 14 years with the disease. 396 00:25:41,895 --> 00:25:46,127 And that's all within the same family, more or less. And so it's 397 00:25:46,311 --> 00:25:50,567 something where longitudinal biomarkers in the same person, just 398 00:25:50,591 --> 00:25:53,995 the power behind that should not be underestimated. 399 00:25:54,375 --> 00:25:58,447 IRIS actually started out in the field of proteomics looking at 400 00:25:58,511 --> 00:26:04,927 a neurodegenerative problem. I'm coming full circle now. Back 401 00:26:04,951 --> 00:26:08,543 then we developed next generation proteomics technologies, 402 00:26:08,679 --> 00:26:12,907 which is just a time when we transitioned from 2D gels to liquid 403 00:26:12,931 --> 00:26:16,027 chromatography, mass spectrometry. And so back then we 404 00:26:16,051 --> 00:26:20,595 were looking at CSF and we could see beautiful patterns of proteins 405 00:26:20,675 --> 00:26:26,803 changing. The challenge back then was taking out these spots that 406 00:26:26,819 --> 00:26:29,507 were detected by silver staining and then characterizing 407 00:26:29,531 --> 00:26:34,131 them by mass spectrometry. And back then the resolution was not 408 00:26:34,203 --> 00:26:38,307 good enough to actually say this is the specific form of protein 409 00:26:38,371 --> 00:26:43,921 that migrates on the gel. Obviously technologies have improved 410 00:26:43,953 --> 00:26:49,321 a lot to the point where you said we use almost assays with single 411 00:26:49,353 --> 00:26:52,977 molecule detection sensitivity to pick up these very small amounts 412 00:26:53,001 --> 00:26:59,289 of phosphatid in blood. But work in proteomics from your perspective, 413 00:26:59,377 --> 00:27:05,343 help in the research as well as in future tools for diagnosis. 414 00:27:05,529 --> 00:27:09,827 Yeah, I think the. So particularly coming from the tau 415 00:27:09,891 --> 00:27:13,575 field. Right. Tau is a intrinsically disordered protein. 416 00:27:13,875 --> 00:27:20,187 So it means it's very like, it is very floppy, it doesn't form a 417 00:27:20,211 --> 00:27:23,379 crystal structure. Right. So it's been very difficult to nail 418 00:27:23,427 --> 00:27:26,763 down. Like what is the form of tau that causes disease? I would 419 00:27:26,779 --> 00:27:29,155 argue to this day we still don't know that question. 420 00:27:29,235 --> 00:27:29,595 Right. 421 00:27:29,675 --> 00:27:33,561 We do not know the form of tau that actually leads to neuronal death. 422 00:27:33,673 --> 00:27:36,913 We have a lot of guesses. Right. But this is where also I think 423 00:27:36,969 --> 00:27:41,689 when you think of which protein biomarker using proteomics, 424 00:27:41,817 --> 00:27:45,441 understanding and trying to like understand the native state, 425 00:27:45,553 --> 00:27:49,025 not applying too many harsh detergents, because you can change 426 00:27:49,065 --> 00:27:52,569 the phospho status, you can change. I mean, tau is phosphorylated, 427 00:27:52,617 --> 00:27:54,977 it's simulated, it's ubiquitated, it's methylated. Like 428 00:27:55,081 --> 00:27:58,753 anything that's like aided tau has it at some point, it also gets 429 00:27:58,769 --> 00:28:02,401 cleaved in different places. And these all probably mean something 430 00:28:02,553 --> 00:28:05,405 over the course of disease, but we've just not been able to really 431 00:28:05,445 --> 00:28:08,517 understand that because we didn't have the assays in terms of 432 00:28:08,701 --> 00:28:11,357 you are at the whims of your pull down, for example, for a very 433 00:28:11,381 --> 00:28:14,957 long time, what antibody, what epitope are you pulling down? That 434 00:28:14,981 --> 00:28:19,253 will change your entire readout. So being able to understand 435 00:28:19,309 --> 00:28:23,373 more unbiased what exists in the blood helps us understand, there's 436 00:28:23,389 --> 00:28:25,797 the biomarker piece in terms of disease progression, but that 437 00:28:25,821 --> 00:28:28,973 also helps us understand. All right, is that the form of tau that 438 00:28:28,989 --> 00:28:32,205 we think could be leading to neuronal death. Does that help us 439 00:28:32,245 --> 00:28:35,541 understand therapeutics better? Right. So If I know Phosphatau 440 00:28:35,573 --> 00:28:40,197 217, if that is a major culprit in the pathogenesis of the 441 00:28:40,221 --> 00:28:44,605 disease. Now I know, okay, let's build a therapeutic that can 442 00:28:44,645 --> 00:28:47,509 basically prevent the phosphorylation of that specific 443 00:28:47,557 --> 00:28:49,757 site. If I think it's just that site, I don't think it's just 444 00:28:49,781 --> 00:28:54,661 that site. But it helps then feed back into drug discovery, drug 445 00:28:54,733 --> 00:28:57,981 development. It allows us to approach therapeutics from a totally 446 00:28:58,013 --> 00:29:01,271 different angle that perhaps we just had no idea about previously. 447 00:29:01,453 --> 00:29:04,523 And then it allows the field to move forward in terms of biology 448 00:29:04,579 --> 00:29:08,323 understanding. And ultimately we're doing all of this to try and 449 00:29:08,339 --> 00:29:12,963 cure patients. Right. Like that's the goal is to cure the disease. 450 00:29:13,139 --> 00:29:18,091 And so understanding these smaller protein changes, what does 451 00:29:18,123 --> 00:29:21,259 that mean? What's coming from your brain? What's within your peripheral 452 00:29:21,307 --> 00:29:24,747 compartment? Right. We talked about big tau, for example, which 453 00:29:24,771 --> 00:29:28,883 I love that it's actually called big tau. It's amazing. I think 454 00:29:28,899 --> 00:29:32,361 it was coined by Michelle Godere and it's, it's one of those, 455 00:29:32,393 --> 00:29:33,977 right. Where it's like you have a lot of tau in your peripheral 456 00:29:34,001 --> 00:29:37,841 compartment as well. How do you separate out brain from periphery? 457 00:29:37,953 --> 00:29:40,401 We can use proteomics to do that. They're very different sizes. 458 00:29:40,473 --> 00:29:46,377 Peripheral tau has several more exons. It's huge. It's like 459 00:29:46,401 --> 00:29:47,681 almost double in size, Correct? 460 00:29:47,713 --> 00:29:48,041 Yeah. 461 00:29:48,113 --> 00:29:50,809 And so it allows you then to say like, okay, what is actually 462 00:29:50,857 --> 00:29:53,177 coming from brain? Because that, that's plagued the field for 463 00:29:53,201 --> 00:29:54,953 a pretty long time. Right. When you think of something like 464 00:29:54,969 --> 00:29:58,265 neurofilament light there, it's tricky to understand what is 465 00:29:58,305 --> 00:30:01,921 peripherally derived versus brain derived. But we can use, for 466 00:30:01,953 --> 00:30:05,729 Alzheimer's we can say what is, you know, amyloid beta is typically 467 00:30:05,777 --> 00:30:11,001 just brain centric tau. We can use proteomics to understand what's 468 00:30:11,033 --> 00:30:15,585 peripheral versus cns. We can then say like, what is phosphorylated 469 00:30:15,625 --> 00:30:17,281 within the peripheral compartment, what's phosphorylated 470 00:30:17,313 --> 00:30:20,913 in the brain? And it all leads to understanding the biology and 471 00:30:20,929 --> 00:30:22,557 then that feeds into therapeutics. 472 00:30:22,681 --> 00:30:26,757 I agree with you. Tau protein is a, the tau protein itself is a 473 00:30:26,781 --> 00:30:31,429 very fascinating protein. When I think about those phosphorylations, 474 00:30:31,517 --> 00:30:36,117 I think about literally timestamps that whatever goes on 475 00:30:36,141 --> 00:30:39,549 in the brain leaves on that molecule. Obviously it's healthily 476 00:30:39,597 --> 00:30:42,685 filtered by the time it arrives in blood, but it's still 477 00:30:42,725 --> 00:30:46,797 sort of like a peek inside what's going on with respect to the 478 00:30:46,821 --> 00:30:51,353 biology in Your brain. And so I wonder whether there's a lot of 479 00:30:51,409 --> 00:30:55,065 conversation around the fact that Alzheimer's is the symptom, 480 00:30:55,105 --> 00:30:59,645 but the causes can be very different. And in fact there is, 481 00:31:00,025 --> 00:31:03,665 I think, a consensus emerging that there may be several driving 482 00:31:03,745 --> 00:31:09,529 forces behind it. The death of synapses, maybe part of an immune 483 00:31:09,577 --> 00:31:13,049 reaction, there's clearly inflammation involved, as you already 484 00:31:13,097 --> 00:31:17,935 mentioned. So where do you think proteomics needs to be helping 485 00:31:17,975 --> 00:31:21,767 and clarifying this? Obviously you're not going to do this on the 486 00:31:21,791 --> 00:31:24,631 patient, you're going to be doing this in animal models, for 487 00:31:24,663 --> 00:31:28,471 example. What's the role maybe of proteomics in animal models or 488 00:31:28,503 --> 00:31:30,967 any type of other model, alternate model. 489 00:31:31,071 --> 00:31:35,555 Yeah. Animal models are tricky because there is no perfect model 490 00:31:36,935 --> 00:31:43,593 there. I think very pointed hypotheses are essential. And stapling 491 00:31:43,729 --> 00:31:46,753 essentially several different models together. So if you have convergence 492 00:31:46,809 --> 00:31:50,585 across IPSC cells, for example, so if you take a fibroblast 493 00:31:50,625 --> 00:31:53,257 and then I differentiate them into neurons or a different cell 494 00:31:53,281 --> 00:31:56,817 type, microglia, astrocytes, and then I've got a mouse model where 495 00:31:56,841 --> 00:32:00,925 I've either knocked something in specifically to address one hypothesis. 496 00:32:01,745 --> 00:32:05,769 Can you move up to non human primates, for example, to get larger 497 00:32:05,817 --> 00:32:09,403 volumes, to understand more of like a natural state? Putting all 498 00:32:09,419 --> 00:32:12,875 of those together is hugely important, right? Because if you 499 00:32:12,915 --> 00:32:17,763 only isolate and like rely on just one model, like, you are lost, 500 00:32:17,899 --> 00:32:22,295 in my opinion, because it's just every model has huge caveats 501 00:32:23,515 --> 00:32:26,179 in terms of where I think proteomics can help out a lot. I 502 00:32:26,187 --> 00:32:31,307 think it's, for me a huge gap is still the understanding of what 503 00:32:31,371 --> 00:32:35,555 neuroinflammatory signatures change when, over the course of the 504 00:32:35,595 --> 00:32:39,905 disease and moving earlier and earlier. So we know my beta plaque 505 00:32:39,945 --> 00:32:43,865 starts 20 years prior, what does that mean for microglial signatures? 506 00:32:44,025 --> 00:32:47,217 Can we look at plasma? Can we understand what goes up, what goes 507 00:32:47,241 --> 00:32:52,817 down at different time points? Even for hyperexcitability, for example, 508 00:32:52,961 --> 00:32:56,601 there is a certain group of people who believe hyperexcitability 509 00:32:56,673 --> 00:32:59,969 is involved in early Alzheimer's disease. Then you move 510 00:32:59,977 --> 00:33:04,615 to hypo excitability. So the timing is just so, so important. 511 00:33:05,275 --> 00:33:09,275 And I think shifting earlier and earlier and earlier is going 512 00:33:09,275 --> 00:33:12,419 to be really, really helpful and important. Mouse models that 513 00:33:12,427 --> 00:33:15,059 we use for Alzheimer's disease, we slam it right? Like, 514 00:33:15,107 --> 00:33:21,131 we push it super hard. So coming up with more gentle models, 515 00:33:21,283 --> 00:33:23,779 it's painful from a drug discovery and development perspective 516 00:33:23,827 --> 00:33:25,651 because now I got to wait a year and a half for that mouse to 517 00:33:25,683 --> 00:33:28,483 age, right? And we don't like to wait a year and a half. We like 518 00:33:28,499 --> 00:33:31,787 to go fast. We want a model. It's like in six weeks I'm done. 519 00:33:31,811 --> 00:33:35,179 I've got all my pathology. But I do think that if we're going to 520 00:33:35,227 --> 00:33:39,387 go after prodromal Alzheimer's disease, prevent, which I still think 521 00:33:39,411 --> 00:33:42,851 is going to be the best course of action, we do need to form those 522 00:33:42,883 --> 00:33:45,811 more gentle models, those ones that have a bit more of a slow ramp 523 00:33:45,883 --> 00:33:50,019 up and then in humans start to just collect a lot more data from 524 00:33:50,067 --> 00:33:52,443 those. And we can use some genetics. Right. We can take the 525 00:33:52,459 --> 00:33:56,339 APOE 4 population, we can kind of start to tease all of that out. 526 00:33:56,387 --> 00:33:58,299 But we really need to shift earlier and earlier. 527 00:33:58,387 --> 00:34:02,079 Yeah, I mean, I agree with you that, you know, these models will 528 00:34:02,167 --> 00:34:06,135 play a tremendous role studying Alzheimer's disease because 529 00:34:06,215 --> 00:34:10,599 you literally have no access to a living brain. What I think appreciate 530 00:34:10,647 --> 00:34:14,647 from your conversation or from our conversation here is that we 531 00:34:14,671 --> 00:34:18,315 can use these models in very specific ways to ask very specific 532 00:34:19,015 --> 00:34:23,567 questions and eliminate all the other variables that typically 533 00:34:23,671 --> 00:34:28,681 confound any type of discovery. And of course, very accessible 534 00:34:28,713 --> 00:34:32,353 at that point to, you know, current and future preomics technologies. 535 00:34:32,409 --> 00:34:36,441 Yeah. So thinking about the future, you know, looking forward 536 00:34:36,513 --> 00:34:42,409 10 years, what do you hope to see, you know, in diagnosis and maybe 537 00:34:42,457 --> 00:34:44,085 treatment in other areas? 538 00:34:44,505 --> 00:34:50,185 I mean, I would love to see us move to more prodromal studies. So, 539 00:34:50,225 --> 00:34:54,707 you know, Biogen, esai, they have their prodromal a trial for 540 00:34:54,731 --> 00:34:57,859 Alzheimer's. It's the ahead trial. So they're taking their lecanumab 541 00:34:57,907 --> 00:35:01,211 drug and they're starting treatment in people who are prone 542 00:35:01,283 --> 00:35:05,003 to Alzheimer's. Right. So they look at apoe, they look at age, look 543 00:35:05,019 --> 00:35:09,323 at family history. I think Donanemab is also doing the same 544 00:35:09,339 --> 00:35:11,947 thing. So Lily's taking Donanemab, they're also doing prodromal 545 00:35:11,971 --> 00:35:14,923 trials. So moving in that direction again, shifting earlier 546 00:35:14,979 --> 00:35:18,051 and earlier before you have tau pathology, that's really kicking 547 00:35:18,083 --> 00:35:22,391 up. I, I'm super excited to see what those trials look like. 548 00:35:22,503 --> 00:35:25,143 People don't know that Alzheimer's starts like that early. 549 00:35:25,199 --> 00:35:28,199 Right. It's not really counterintuitive. It's weird to think 550 00:35:28,367 --> 00:35:32,735 you're totally fine and your brain is like filling with plaque. 551 00:35:32,895 --> 00:35:37,071 It's just, it's kind of weird. So like for me, like, I know I probably 552 00:35:37,103 --> 00:35:41,439 have plaque starting to form in my brain. I feel fine. And then 553 00:35:41,527 --> 00:35:45,743 it's just a slow roll over 20, 25 years. Like there's not a lot 554 00:35:45,759 --> 00:35:50,405 of other diseases that have like that like long pathology buildup 555 00:35:50,825 --> 00:35:53,817 to get to a point. And then when you're at that point, then it's 556 00:35:53,881 --> 00:35:57,217 so hard to reverse like we are the moment we're in now. The fact 557 00:35:57,241 --> 00:36:02,185 that they could see 25, 30% rescue is pretty remarkable. I'm 558 00:36:02,305 --> 00:36:06,205 taking a page out of the oncology space. Right. Go earlier 559 00:36:06,865 --> 00:36:11,513 and just trying to mimic Alzheimer's disease after oncology. 560 00:36:11,649 --> 00:36:16,091 So can we have, you know, a standard blood based test when you 561 00:36:16,123 --> 00:36:19,267 turn 40? If you have a family history of Alzheimer's, maybe We 562 00:36:19,291 --> 00:36:23,939 start at 35. Can we identify amyloid beta? Is there a neuroinflammatory 563 00:36:23,987 --> 00:36:27,139 signature that we can pick up? Just trying to get more accurate 564 00:36:27,267 --> 00:36:31,555 early on such that, you know, when you are 50? Yep. We should maybe 565 00:36:31,595 --> 00:36:35,619 start an anti amyloid beta therapy and we can bring that cost 566 00:36:35,667 --> 00:36:40,641 down over time and then just start to do more of like a prophylactic 567 00:36:40,763 --> 00:36:44,341 therapy such that you never even show any symptom. Because trying 568 00:36:44,373 --> 00:36:48,237 to reverse something in the brain, so difficult. Right. You only 569 00:36:48,261 --> 00:36:51,757 have a certain number of neurons and when those go, they're 570 00:36:51,781 --> 00:36:54,965 not coming back. Right. We can try and play around with like maybe 571 00:36:55,005 --> 00:36:57,093 you can get a few more synapses. Right. If we clear out 572 00:36:57,109 --> 00:37:00,853 all the tau pathology, maybe you can reverse a few aspects of 573 00:37:00,869 --> 00:37:03,685 the disease, but that has to get borne out. That has not been 574 00:37:03,725 --> 00:37:08,405 proven yet. Way easier just to prevent the death from ever happening 575 00:37:08,445 --> 00:37:12,165 to begin with. So I'm very excited to see more prodromal trials 576 00:37:12,205 --> 00:37:16,361 kick up on the other side for those who do have mild or moderate 577 00:37:16,393 --> 00:37:20,233 Alzheimer's. I'm also very excited to see more tau therapeutics, 578 00:37:20,289 --> 00:37:23,417 ones that we think can actually reverse the pathology. So 579 00:37:23,441 --> 00:37:27,273 you think of the ASOs, the antisense oligos out there. There 580 00:37:27,289 --> 00:37:29,913 are some people thinking of zinc finger transcription factors, 581 00:37:29,969 --> 00:37:32,985 ways of just lowering the total protein levels, because preclinically 582 00:37:33,025 --> 00:37:36,521 it's been shown to reverse tau pathology. And as of last year in 583 00:37:36,553 --> 00:37:40,851 March, adp, Biogen and IONA showed that the tau ASO in their 584 00:37:40,883 --> 00:37:43,803 trials, well, given intrathecally, not the ideal route 585 00:37:43,859 --> 00:37:47,443 per se, but in human patients was able to reverse tau pathology 586 00:37:47,499 --> 00:37:51,051 there. And so it allows us to test the hypothesis. Right. Just 587 00:37:51,083 --> 00:37:54,443 like an amyloid beta therapy, we saw a target engagement, we saw 588 00:37:54,459 --> 00:37:57,563 a reduction of amyloid beta plaque. We know that in MCI patients 589 00:37:57,619 --> 00:38:01,667 that translates to 25 to 30% improvement. Now we get to test the 590 00:38:01,691 --> 00:38:05,495 hypothesis of if I reverse tau pathology, what does that mean for 591 00:38:05,535 --> 00:38:08,711 patients, what does that mean for neuronal death, what does that 592 00:38:08,743 --> 00:38:12,879 mean for cognitive decline? And so having both of those pieces 593 00:38:12,967 --> 00:38:16,215 will allow us to understand what's the best Place to target amyloid 594 00:38:16,255 --> 00:38:21,015 beta or tau. An advent of neuroinflammation therapeutics rate. 595 00:38:21,055 --> 00:38:24,271 We're moving in that direction as well. It's further behind. So 596 00:38:24,303 --> 00:38:28,119 I'm curious to see kind of where that nests in. I also hope 597 00:38:28,167 --> 00:38:31,111 that it's going to be probably closer to the end of those 10 years, 598 00:38:31,183 --> 00:38:35,483 but combination therapies, Alzheimer's, super complex. I think 599 00:38:35,499 --> 00:38:39,747 we are a bit naive to think that one target is going to solve 600 00:38:39,851 --> 00:38:43,675 all of it. And so we have to build the individual ones first, 601 00:38:43,835 --> 00:38:46,611 understand what those mean. And then I'm hoping we can start 602 00:38:46,643 --> 00:38:51,971 to combine them to like to land on a cure. Not a slowing, but 603 00:38:52,003 --> 00:38:54,475 an actual like cure for the disease. 604 00:38:54,595 --> 00:38:58,635 So what I hear you saying is there's lots of avenues we're already 605 00:38:58,715 --> 00:39:03,557 pursuing. Some of them are really hopeful. But what I also hear 606 00:39:03,581 --> 00:39:06,797 you saying is that hopefully the treatments we're looking at is 607 00:39:06,821 --> 00:39:14,541 not just early but also personalized. So whatever accelerates 608 00:39:14,573 --> 00:39:18,829 the particular disease in your brain can be discovered early and 609 00:39:18,837 --> 00:39:22,045 then treated in a personalized way. I can clearly tell you're very 610 00:39:22,085 --> 00:39:26,025 passionate about this. And I think as long as we have many passionate 611 00:39:26,065 --> 00:39:28,625 people like yourself in the field, we're making the progress 612 00:39:28,665 --> 00:39:29,873 you just described. 613 00:39:30,049 --> 00:39:34,673 Yeah, it's, you know, I love diving into the details. The devil's 614 00:39:34,689 --> 00:39:38,129 always in the details with these things, right. And so, I mean, 615 00:39:38,257 --> 00:39:42,081 having focused on Tao for so long and working with the ASOs, seeing 616 00:39:42,113 --> 00:39:46,705 the power that that shows right now, going back, working with 617 00:39:46,745 --> 00:39:50,073 the new group I'm with now, right, Being able to like take some 618 00:39:50,089 --> 00:39:54,809 of these newer ideas, spin out little companies, I mean, trying 619 00:39:54,937 --> 00:39:57,377 basically throw the kitchen sink at it. And I throw the kitchen 620 00:39:57,401 --> 00:39:59,113 sink, I'm throwing the bathroom sink from the garage, I'm 621 00:39:59,129 --> 00:40:03,057 throwing all the sinks at it. Because it's so important that we 622 00:40:03,121 --> 00:40:06,761 find a cure for this disorder. It will destroy the health care system. 623 00:40:06,833 --> 00:40:09,961 Right. As you had mentioned earlier, the aging population is 624 00:40:09,993 --> 00:40:13,769 going up. It's a burden on like the person themselves. It's 625 00:40:13,777 --> 00:40:16,337 a burden on the healthcare, but it's a huge burden on family 626 00:40:16,401 --> 00:40:20,147 members, on just society in general. And as we all move and get 627 00:40:20,171 --> 00:40:24,315 older, as we're making huge waves in oncology, right, we're curing 628 00:40:24,355 --> 00:40:27,283 just so many different cancers. So population is going to 629 00:40:27,299 --> 00:40:30,455 get older and older and older becomes much more pressing. And so 630 00:40:31,035 --> 00:40:35,067 I'm excited to keep moving in this space. I'm very passionate about 631 00:40:35,091 --> 00:40:38,147 it. If we cure Alzheimer's, maybe I become an event planner. 632 00:40:38,211 --> 00:40:44,027 I get out of sight, like I'm here for that reason. And so I to 633 00:40:44,051 --> 00:40:48,179 be in the moment of watching this wave, watching the exponential 634 00:40:48,227 --> 00:40:52,147 growth when it comes to therapeutics, it's so much fun and 635 00:40:52,211 --> 00:40:56,723 it really gets you excited. It feels tangible. It really feels in 636 00:40:56,739 --> 00:41:00,939 the next five to 10 years, we're going to move in a very good 637 00:41:00,987 --> 00:41:01,615 direction. 638 00:41:01,995 --> 00:41:05,091 Perfect. Yeah. I mean, as someone with a family member who 639 00:41:05,123 --> 00:41:08,547 also suffers from neurodegenerative disease, as you 640 00:41:08,571 --> 00:41:12,707 said, it's a burden to the family and certainly burden to the 641 00:41:12,731 --> 00:41:17,427 society. If you just imagine a big city like New York has 10,000 642 00:41:17,491 --> 00:41:20,987 people who are lost, just taking care of those people who may 643 00:41:21,011 --> 00:41:25,979 be lost somewhere is a huge burden. So I'm with you on the passion 644 00:41:26,027 --> 00:41:30,875 side. I'm on the tool side and hopefully the combination of new 645 00:41:30,915 --> 00:41:34,267 tools and clinical trials and new approaches, our business approaches 646 00:41:34,291 --> 00:41:37,135 as well, sort of crack that problem. 647 00:41:37,445 --> 00:41:38,661 Yeah, absolutely. 648 00:41:38,813 --> 00:41:42,725 With that. Thank you so much, Sara, for your insightful conversation. 649 00:41:42,845 --> 00:41:43,893 I really appreciate it. 650 00:41:43,949 --> 00:41:47,237 Yeah. Thank you for having me and giving me a medium to talk about 651 00:41:47,301 --> 00:41:51,373 tau, my passion, Alzheimer's. It's been a ton of fun. 652 00:41:51,509 --> 00:41:52,021 Thank you. 653 00:41:52,093 --> 00:41:52,705 Thanks. 654 00:41:55,845 --> 00:41:59,557 We hope you enjoyed the Translating Proteomics podcast brought 655 00:41:59,581 --> 00:42:03,581 to you by Nautilus Biotechnology. To contact us or for 656 00:42:03,613 --> 00:42:07,973 further information, please email translatingproteomicsautilus 657 00:42:08,069 --> 00:42:08,245 Bio.